

| | |
|--|---|
| Investigator Name: Site Name: Site Address: Phone Number: | Emeka M. Eziri, MD, MS, FCCP Carolina Clinical Research 9040 Nations Ford Road, Charlotte, NC 28273 704-290-4587 |
|--|---|

| Education: Medical School and Post-Graduate Studies |
|--|
| <p>New York University Robert F. Wagner Graduate School of Public Service Master of Science in Management May 2001 New York, NY 10012</p> <p>Albert Einstein College of Medicine Montefiore Medical Center, The University Hospital of AECOM Fellowship Training in Critical Care Medicine August 2001 Bronx, NY 10467</p> <p>Albert Einstein College of Medicine Bronx Lebanon Hospital Center Fellowship Training in Pulmonary Disease Medicine July 1999 Bronx, NY 10457</p> <p>Mount Sinai School of Medicine North General Hospital Internship and Residency in Internal Medicine July 1997 New York, NY 10035</p> <p>University of Calabar College of Medicine Degree: MD Specialization: Medicine, Surgery 1988 Calabar, Nigeria</p> |

Clinical Research Experience

Clinical Investigator, Carolina Clinical Research (CCR)
Charlotte, NC 28273
July 2019 – Present

Clinical Investigator, Vitalink Research -Gastonia
(Effective 01 SEP 2016, Gastonia Pharmaceutical Research is d/b/a Vitalink Research-
Gastonia)
Gastonia, NC 28054
Jan. 2014 – May 2018

PCC Clinical Research
Huntersville, NC 28078
Oct. 2008 - December 2012

Board Certification

American Board of Internal Medicine-1997, 2010
American board of Internal Medicine-Pulmonary-2004, 2012
American Board of Quality Assurance & Utilization Review Physicians-1997

Fellowships and Licensure

Fellow, American College of Chest Physicians
Fellow, American Institute for Healthcare Quality
Fellow, American Board of Quality Assurance &
Utilization Review Physicians
Good Clinical Practice

Medical and Dental Council of Nigeria
1988-Present
North Carolina Medical Board
2001-Present
South Carolina Medical Board
2015-Present
Florida Medical Board
2016 - Present

Professional Experience

Englewood Hospital and Medical Center
House Physician, Department of Medicine
Englewood, NJ
1999-2001

Medcare of East Rutherford
Urgent Care Physician
East Rutherford, NJ
1999-2000

Pulmonary Clinic of the Carolina's PC
Medical Director
Lincolnton, NC
2001-Present

Sleep Medix Consultant
Lekki, Lagos, Nigera
2012-2013

Hospital Affiliations

Atrium Health, Lincolnton NC
Caromont Regional Medical Center, Gastonia NC
Kings Mountain Hospital, Kings Mountain, NC
Novant Health Huntersville Medical Center, Huntersville, NC

Sponsors and Studies

Chiesi

A phase II, 8 week, randomized, double-blind, placebo and active controlled, parallel group, dose ranging study to evaluate the efficacy and safety of 3 doses of CHF 718 PMDI (beclomethasone dipropionate) in asthmatic subjects.

Protocol: CCD-05993AA3-01

July 2017 – Ongoing (Study ongoing but no longer serving as PI)

Expected Enrollment: 6 subjects randomized

Actual Enrollment: 8 subjects randomized prior to departure from PI role

GlaxoSmithKline

A phase III, 52 week, randomized, double-blinded, 3-arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF/UMEC/VI with the fixed dose dual combinations of FF/VI and UMEC/VI, all administered once-daily in the morning via a dry powder inhaler in subjects with chronic obstructive pulmonary disease

Protocol: CTT116855

Jul 2014-Aug 2016

Expected Enrollment: 12

Actual Enrollment: 29

Novartis

A 26 week, randomized, active-controlled safety study of double-blind Formoterol fumarate in free combination with an inhaled corticosteroid Steroid an inhaled corticosteroid in adolescent and adult patients with persistent asthma

Protocol: CFOR258D2416

Nov 2014-Jul 2016

Expected Enrollment: 10

Actual Enrollment: 21

Sunovion Therapeutics

A comparative effectiveness and safety study of Arformoterol Tartrate Inhalation solution and Tiotropium bromide on re-hospitalization in Chronic obstructive pulmonary disease (COPD) subjects (a phase III study) **Protocol: SEP091-402**

Mar 2015-Dec 2016

Expected Enrollment: Open enrollment

Actual Enrollment: 17

Pearl Therapeutics

A randomized, double-blinded, chronic dosing (24 weeks), placebo-Controlled. Parallel group, multi-center study to assess the efficacy And safety of PT003, PT005, and PT001 in subjects with moderate To very severe COPD, compared with placebo

Protocol: PT003014 Apr 2015-Jul 2016

Expected Enrollment: 10

Actual Enrollment: 15

GlaxoSmithKline

Mepolizumab vs. Placebo as add-on treatment for frequently exacerbating COPD patients characterized by eosinophil level

Protocol: MEA117113

Aug 2015-Jan 2017

Expected Enrollment: 6

Actual Enrollment: 10

Theravance

A phase 3, 12-week, randomized, double-blinded placebo-controlled Parallel-group study of nebulized TD-4208 in subjects with Chronic Obstructive Pulmonary Disease

Protocol: TD-4208-0126

Oct 2015-Nov 2016

Expected Enrollment: 10

Actual Enrollment: 21

Signature and date: _____

Melika Lyul Jan 17 2020